Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Prochlorperazine: Dopamine D2 Antagonist for Melanoma and...

    2026-01-23

    Prochlorperazine: Dopamine D2 Antagonist for Melanoma and Antiemetic Research

    Executive Summary. Prochlorperazine is a phenothiazine derivative that antagonizes the dopamine D2 receptor and inhibits histamine, muscarinic, and adrenergic receptors [APExBIO]. It demonstrates antiemetic effects by blocking central dopamine signaling and shows potent inhibition of melanoma cell proliferation at low micromolar concentrations (Otręba et al. 2019). The compound impairs melanoma cell migration and downregulates MITF and tyrosinase, key regulators of melanogenesis. Prochlorperazine also exhibits antiviral activity via clathrin-mediated endocytosis inhibition. Safety profiles include risks of extrapyramidal symptoms and rare neuroleptic malignant syndrome, necessitating careful application in research and clinical contexts.

    Biological Rationale

    Prochlorperazine (CAS No. 58-38-8) belongs to the phenothiazine class and is structurally related to other neuroleptics. It is widely used clinically for controlling severe nausea and vomiting, as well as in migraine management [see related]. The compound’s antiemetic utility arises from dopamine D2 receptor antagonism in the medullary chemoreceptor trigger zone. Recent studies extend its relevance to oncology, where Prochlorperazine demonstrates the capacity to inhibit melanoma cell viability and motility by interfering with melanocyte-specific transcriptional pathways (Otręba et al. 2019). Its additional antiviral activities are attributable to disruption of endocytic trafficking. The breadth of action makes Prochlorperazine a valuable research tool in both neuropharmacology and cancer biology [mechanistic overview].

    Mechanism of Action of Prochlorperazine

    • Dopamine D2 receptor antagonism: Prochlorperazine blocks D2 receptors in the brain, particularly in the chemoreceptor trigger zone, providing antiemetic effects [APExBIO].
    • Histamine, muscarinic, and adrenergic receptor blockade: It acts as an antagonist at H1/H2, muscarinic cholinergic, and α1/α2 adrenergic receptors, contributing to its pharmacological profile.
    • Inhibition of clathrin-mediated endocytosis: Prochlorperazine disrupts cellular entry of viruses by blocking clathrin-dependent internalization, underlying its antiviral properties [see mechanistic update].
    • Modulation of MITF and tyrosinase: In melanoma cells, it downregulates microphthalmia-associated transcription factor (MITF) and tyrosinase, thereby impairing melanogenesis and cell survival (Otręba et al. 2019).

    Evidence & Benchmarks

    • Prochlorperazine inhibits proliferation of human melanoma COLO829 cells with an EC50 of 3.76 ± 0.14 μM (72 h, RPMI1640 medium, 37°C, 5% CO2) (Otręba et al. 2019).
    • In amelanotic C32 melanoma cells, EC50 is 2.90 ± 0.17 μM under identical conditions (Otręba et al. 2019).
    • Prochlorperazine reduces MITF and tyrosinase protein levels, key regulators of melanocyte survival and differentiation (Otręba et al. 2019).
    • Typical in vitro assay concentrations: 1–10 μM for viability; 1–4 μM for migration (wound healing assays) (APExBIO).
    • Prochlorperazine is insoluble in water, but soluble in DMSO (≥16.5 mg/mL) and ethanol (≥58.5 mg/mL) (APExBIO).
    • Clinical dosing: 5–10 mg orally or intravenously, administered multiple times daily for antiemetic therapy (APExBIO).

    This extends the mechanistic focus of "Prochlorperazine: Dopamine D2 Antagonist for Antiemetic…" by providing quantitative EC50 values and direct links to melanoma research applications.

    Applications, Limits & Misconceptions

    Prochlorperazine’s utility spans antiemetic, anticancer, and antiviral research. It is used as a reference agent for dopamine signaling blockade and as a tool to evaluate resistance mechanisms in melanoma and breast cancer models [see workflow guidelines]. Research applications include:

    • Antiemetic controls in neuropharmacological assays.
    • Assessment of MITF/tyrosinase pathway modulation in melanoma biology.
    • Antiviral compound screening via clathrin-mediated endocytosis inhibition.
    • Tamoxifen-resistant breast cancer proliferation studies.

    Common Pitfalls or Misconceptions

    • Prochlorperazine is not effective against all cancer types; its activity is most pronounced in melanoma and specific breast cancer models (Otręba et al. 2019).
    • It is not soluble in aqueous buffers; improper solvent use can invalidate results (APExBIO).
    • Long-term storage of stock solutions is not recommended; solid storage at -20°C is preferred (APExBIO).
    • Clinical administration is contraindicated in severe cardiovascular disease or known hypersensitivity (APExBIO).
    • Neuroleptic malignant syndrome, although rare, is a serious risk and must be monitored (APExBIO).

    Workflow Integration & Parameters

    In vitro protocol: Prochlorperazine is typically dissolved in DMSO or ethanol to prepare stock solutions (≥16.5 mg/mL in DMSO; ≥58.5 mg/mL in ethanol). Working concentrations for cell-based assays range from 1–10 μM for proliferation and cytotoxicity, and 1–4 μM for migration (wound healing) studies. Solutions should be freshly prepared due to stability constraints. The compound is best stored as a solid at -20°C. For antiemetic studies, dosing in animal models or clinical analogues is 5–10 mg per administration, adjusted for route and frequency.

    Researchers are advised to refer directly to the APExBIO Prochlorperazine (A8508) product page for up-to-date protocols, safety, and solubility data. This complements the protocol optimization focus in "Prochlorperazine (SKU A8508): Optimizing Cell Assays and…" by aligning experimental parameters with mechanistic outcomes.

    Conclusion & Outlook

    Prochlorperazine is a validated dopamine D2 receptor antagonist with robust antiemetic, anticancer, and antiviral research applications. Its capacity to inhibit melanoma proliferation and migration, modulate MITF and tyrosinase, and block clathrin-mediated endocytosis is well-documented in peer-reviewed literature. Limitations include solubility challenges and safety boundaries. APExBIO provides a reliable source for research-grade Prochlorperazine, facilitating reproducible results across oncology and pharmacology pipelines. Ongoing studies may further clarify its therapeutic value beyond current indications.